NuVasive sees back-to-back growth in Q2 — 4 CEO insights

Spinal Tech

The spine market continued to stabilize in the second quarter as NuVasive reported a 44.8 percent increase in second-quarter net sales compared to the same period last year.

Four insights from the company's second-quarter earnings call, as transcribed by The Motely Fool:

1. This quarter, NuVasive's Simplify Disc achieved FDA approval for two-level cervical total disc replacement — one of only three devices to do so.

"These results, along with early surgeon feedback and adoption, validate our strategic investment and further our continued growth in one of the largest subsegments in spine," CEO Christopher Barry said July 28.

2. A new journal article has demonstrated the ability of NuVasive's single-position spine surgery approach, X360, to decrease hospital stays and maintain similar clinical outcomes to dual-position lumbar fusion.

"These results build on our prior literature validation of X360, a comprehensive system enabling surgeons to access every single level of lumbar spine in lateral, prone lateral, [anterior lumbar interbody fusion], and posterior fixation procedures, all while keeping the patient in a single position," Mr. Barry said.

3. The company's Pulse integrated navigation platform designed to assist surgeons in all spine procedures received FDA approval in July and has begun clinical evaluations in six European countries.

"This differentiated platform helps address some of the most common clinical challenges in spine surgery with radiation reduction, imaging enhancement, rod bending, navigation, intraoperative neuromonitoring, wireless connectivity and spinal alignment technologies," Mr. Barry said.

4. NuVasive increased its investment in research and development year over year to boost innovation in each procedural segment.

Copyright © 2023 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Podcast

Featured Whitepapers